Pelthos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	27.7	16.8	-	-	-	-
Cost of Revenue	6.88	5.22	1.18	-	0.39	0.21
Gross Profit	20.82	11.58	-1.18	-	-0.39	-0.21
Selling, General & Admin	60.9	41.43	6.39	4.28	1.93	0.63
Research & Development	-	-	-	2.58	-	-
Amortization of Goodwill & Intangibles	2.59	1.56	-	-	-	-
Operating Expenses	63.48	42.99	6.39	6.86	1.93	0.63
Operating Income	-42.66	-31.41	-7.57	-6.86	-2.32	-0.84
Interest Expense	-5.23	-3.01	-0.79	-0.52	-0.14	-0
Interest & Investment Income	0.01	0.01	0.4	-	-	-
Other Non Operating Income (Expenses)	-9.78	-14.98	-	-	-	-
EBT Excluding Unusual Items	-57.67	-49.4	-7.96	-7.38	-2.46	-0.84
Merger & Restructuring Charges	-1.02	-1.02	-	-	-	-
Asset Writedown	-0.29	-0.29	-	-	-	-
Other Unusual Items	-	-	-	-	-	0.24
Pretax Income	-58.98	-50.71	-7.96	-7.38	-2.46	-0.6
Income Tax Expense	-7.39	-7.39	-	-	-	-
Net Income	-51.59	-43.32	-7.96	-7.38	-2.46	-0.6
Net Income to Common	-51.59	-43.32	-7.96	-7.38	-2.46	-0.6
Shares Outstanding (Basic)	3	2	1	0	0	-
Shares Outstanding (Diluted)	3	2	1	0	0	-
Shares Change (YoY)	330.61%	237.34%	336.69%	193.25%	-	-
EPS (Basic)	-20.19	-23.04	-14.27	-57.82	-56.48	-
EPS (Diluted)	-20.19	-23.04	-14.27	-57.82	-56.48	-
Free Cash Flow	-35.38	-22.69	-5.79	-0.98	-1.57	-1.59
Free Cash Flow Per Share	-13.85	-12.06	-10.39	-7.68	-36.00	-
Gross Margin	75.16%	68.94%	-	-	-	-
Operating Margin	-154.01%	-187.01%	-	-	-	-
Profit Margin	-186.23%	-257.93%	-	-	-	-
Free Cash Flow Margin	-127.71%	-135.09%	-	-	-	-
EBITDA	-	-29.12	-	-	-1.63	-
EBITDA Margin	-	-173.40%	-	-	-	-
D&A For EBITDA	-	2.29	-	-	0.69	-
EBIT	-42.66	-31.41	-7.57	-6.86	-2.32	-0.84
EBIT Margin	-154.01%	-187.01%	-	-	-	-
Revenue as Reported	27.7	16.8	-	-	-	-

SEC Filings: 10-K · 10-Q